Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Heart and Blood Diseases

Symptoms and General Pathology

Neoplasms

Digestive System Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Gland and Hormone Related Diseases

Nervous System Diseases

Mouth and Tooth Diseases

Ear, Nose, and Throat Diseases

Rare Diseases

Kidney Diseases

Hypertension

Essential Hypertension

Syndrome

Stomach Neoplasms

Lung Neoplasms

Pancreatic Neoplasms

Epilepsy

Acute Coronary Syndrome

Chronic Disease

Liver Neoplasms

Dysbiosis

Nasopharyngeal Carcinoma

Hypothyroidism

Urologic Diseases

Hyperaldosteronism

Endocrine System Diseases

Nasopharyngeal Neoplasms

Carcinoma

Renal Insufficiency, Chronic

Renal Insufficiency

Vascular Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Disease Attributes

Coronary Artery Disease

Myocardial Ischemia

Ischemia

Heart Diseases

Thyroid Diseases

Adrenocortical Hyperfunction

Adrenal Gland Diseases

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Head and Neck Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Chronic Graft Versus Host Disease

Stomach Cancer

Pancreatic Cancer

Acute Graft Versus Host Disease

Hyperadrenalism

no intervention

Jiahui Zhang

Hui Xu

Wenming Wang

Xiaoli Zhang

Yingping Cao

Falin Chen

Yan Chen

Liqiong Yao

Gechong Yong

Tian Cai

Minmin Li

Zhaofan Luo

Kang Chen

Li Xie

Yulin Yuan

Minzhong Tang

Wei Wang

Hai Huang

Xiang Wu

Dejun Yun

Yingyu Jin

Haiyan Gao

Jinyu Yang

Wenxiu Liu

Zhanjun Zhang

Tao Jiang

Weibing Yin

Xiaoliang Zhou

Zhengjiang Cheng

Xuesheng Li

Zuiming Jiang

Guoli Liu

Hongyu Huang

Honghou Dai

Tianyu Zhong

Xiaozhong Wang

Jufen Ma

Kunping Guan

Yuanyuan Pan

Hongli Liu

Zhuo Li

Yuan Liu

Yuanjiu Xu

Yin Xiang

Kai Chen

Heng Zhang

Li Ren

Aimin Xu

Yong Duan

Fuxing Zhang

Yufeng Liao

Yan He

The human gut microbiome has been associated with many health factors but variability between studies limits the exploration of effects between them. This study aims to systematically characterize the gut microbiota of various critical chronic diseases, compare the similarities and differences of the microbiome signatures linked to different regions and diseases, and further investigate their impacts on microbiota-based diagnostic models.

Many studies demonstrate that microbial dysbiosis has been linked to many human pathologies. However, the current understanding of the identification of the disease-associated microbiome signatures remains limited, largely owing to the heterogeneity of microbial community structures which are shaped by the host. Undoubtedly, profiles of microbial biomarkers require validation in large, independent, population-based cohorts from different districts. Based on these, the investigator plan to organize a multicentric cross-sectional cohort, not only to systematically characterize the gut microbiota of various critical chronic diseases, such as liver cancer, gastric cancer, pancreatic cancer, lung cancer, nasopharyngeal cancer, hypertension, acute coronary syndrome, primary aldosteronism, epilepsy, chronic kidney disease, and subclinical hypothyroidism but also to compare the similarities and differences of the microbiome signatures linked to different regions and different diseases and to further investigate their impacts on microbiota-based diagnostic models. In this study, for each kind of disease, the investigators expect to recruit 500 patients with a confirmed diagnosis and 500 sex- and age-matched controls, to record their information related to demography, body measurement, lifestyle, diet, medication, diseases, and biochemistry, and to collect their feces, saliva, urine and blood samples.

Feces, saliva, urine, serum, plasma and buffy coat

A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China

The microbial composition of the stool and saliva samples was determined by 16S rRNA (ribosomal ribonucleic acid) gene sequencing analysis and metagenomics. Comparison of microbial abundance and diversity of healthy volunteers and patients with various diseases.

Comparison of serum markers of healthy volunteers and patients with various diseases.

Comparison of metabolites of healthy volunteers and patients with various diseases.

Comparison of peptides of healthy volunteers and patients with various diseases using mass spectrometry.

National Natural Science Foundation of China

Zhujiang Hospital

Professor

Pheochromocytoma

Paraganglioma

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Paragangliomas 1

Neuroendocrine Tumor

Neuroepithelioma

Anti-Dyskinesia Agents

All Drugs and Chemicals

Vasoconstrictor Agents

Respiratory System Agents

Cardiotonic Agents

Levodopa

Epinephrine

Norepinephrine

Dopamine

Racepinephrine

Epinephryl borate

Dihydroxyphenylalanine

Serotonin

Patients are adults or children of any age with known, sporadic or familial PHEO/PGL

is L 3, 4 dihydroxyphenylalanine (L-DOPA) labeled with the radioactive isotope 18F. In general, PPGLs belong to the group of neuroendocrine tumors. This heterogeneous group of tumors takes up amino acids, transforms them into biogenic amines (dopamine and serotonin) by decarboxylation and stores the amines in vesicles. L DOPA is a precursor of catecholamines (dopamine, norepinephrine and epinephrine). Epinephrine conversion to dopamine is catalyzed by the aromatic amino acid decarboxylase. According to previous and current studies, \[18F\]-DOPA PET is highly sensitive and specific for detection of PHEO/PGL67-69. However, there are only a few reports in the literature using \[18F\]-DOPA as a PET agent and particularly for patients with metastatic PPGLs. PET imaging will be done together with either a CT, an MRI or both modalities.

([18F]-DOPA)

is an imaging agent developed at the NIH, that may improve specificity and sensitivity in the localization of PPGLs. \[18F\]-6F-DA enters cells via the membrane norepinephrine transporter. Once inside cells, \[18F\]-6F-DA is translocated via the vesicular monoamine transporter into storage vesicles, where the radioactivity is concentrated. After injection of \[18F\]-6F-DA, the much faster disappearance of \[18F\]-6F-DA-derived radioactivity from the bloodstream and non-neuronal cells than from chromaffin cells should enable rapid visualization of PPGLs by PET scanning.

([18F]-6F-DA)

Alberta Derkyi, C.R.N.P.

Karel Pacak, M.D.

For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

The goal of this study is to develop better methods of diagnosis, localization, and treatment for pheochromocytomas. These tumors, which usually arise from the adrenal glands, are often difficult to detect with current methods. Pheochromocytomas release chemicals called catecholamines, causing high blood pressure. Undetected, the tumors can lead to severe medical consequences, including stroke, heart attack and sudden death, in situations that would normally pose little or no risk, such as surgery, general anesthesia or childbirth.

Patients with pheochromocytoma may be eligible for this study. Candidates will be screened with a medical history and physical examination, electrocardiogram, and blood and urine tests. Study participants will undergo blood, urine, and imaging tests, described below, to detect pheochromocytoma. If a tumor is found, the patient will be offered surgery. If surgery is not feasible (for example, if there are multiple tumors that cannot be removed), evaluations will continue in follow-up visits. If the tumor cannot be found, the patient will be offered medical treatment and efforts to detect the tumor will continue. Main diagnostic and research tests may include the following:

1. Blood tests - mainly measurements of plasma or urine catecholamines and metanephrines as well as methoxytyramine. If necessary the clonidine suppression test can be carried out.
2. Standard imaging tests - Non-investigational imaging tests include computed tomography (CT), magnetic resonance imaging (MRI), sonography, and 123I-MIBG scintigraphy and FDG (positron emission tomography) PET/CT. These scans may be done before and/or after surgical removal of pheochromocytoma.
3. Research PET scanning is done using an injection of radioactive compounds. Patients may undergo 18F-FDOPA, 18F-DA, as well as 68Ga-DOTATATE PET/CT . Each scan takes up to about 2 hours.
4. Genetic testing - A small blood sample is collected for DNA analysis and other analyses.

Pheochromocytomas (PHEOs) and paragangliomas (PGLs) are rare and clinically important chromaffin cell tumors that typically arise from the adrenal gland or from extra-adrenal paraganglia, respectively. The clinical features and consequences of PHEO/PGL result from the release of catecholamines (norepinephrine and/or epinephrine). An undetected PHEO/PGL poses a hazard to patients undergoing surgery, childbirth, or general anesthesia, due to the potential for excess catecholamine secretion, which can result in significant, often catastrophic outcomes. Diagnosing and localizing a PHEO/PGL can be challenging. Plasma and urinary catecholamines as well as their metabolites and radio-iodinated metaiodobenzylguanidine (MIBG) scanning can yield false-positive/negative results in patients harboring the tumor. Computed tomography (CT) and magnetic resonance imaging (MRI) lack sufficient specificity. The molecular mechanisms by which genotypic changes predispose to the development of PHEO/PGL remain unknown - even in patients with identified pathogenic variants. Moreover, in patients with hereditary predispositions, PHEOs/PGLs differ in terms of their growth, malignant potential, catecholamine phenotype, responses to standard screening tests, various imaging modalities and therefore subsequently, different therapeutic options. This protocol focuses on developmental, molecular, genetic, epigenetic, proteomic, metabolomics, immunologic and other types of studies to investigate the bases for predisposition to develop PHEOs/PGLs and for expression of different neurochemical and other phenotypes and malignant potentials including therapeutic responses. Furthermore, this protocol will also use new imaging approaches, for example \[18F\]-6F-dopamine (\[18F\]-6F-DA), and \[18F\]-L-3,4-dihydroxyphenylalanine (\[18F\]-FDOPA) positron emission tomography (PET)/CT, as well as dynamic contrast-enhanced MRI.

Diagnosis of Pheochromocytoma

Diagnosis, Pathophysiology, and Molecular Biology of Pheochromocytoma and Paraganglioma

To study specific genotypes, biochemical and imaging phenotypes of patients with various pheochromocytomas and paragangliomas.To stuty potential treatment options for metastatic pheochromocytoma and paraganglioma using cell cultures, cell lines, animal

To educate health care professionals and patients about pheochromocytoma and paraganglioma

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China	NCT05638269	Essential Hyper... Liver Cancer Nasopharyngeal ... Pancreatic Canc... Lung Cancer Chronic Kidney ... Acute Coronary ... Epilepsy Gastric Cancer Primary Aldoste... Subclinical hyp...	no intervention	18 Years - 75 Years	Zhujiang Hospital
A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China	NCT05638269	Essential Hyper... Liver Cancer Nasopharyngeal ... Pancreatic Canc... Lung Cancer Chronic Kidney ... Acute Coronary ... Epilepsy Gastric Cancer Primary Aldoste... Subclinical hyp...	no intervention	18 Years - 75 Years	Zhujiang Hospital
Diagnosis of Pheochromocytoma	NCT00004847	Pheochromocytom... Endocrine Disea... Endocrine Disea...	([18F]-DOPA) ([18F]-6F-DA)	3 Years - 120 Years	National Institutes of Health Clinical Center (CC)

Spots Global Cancer Trial Database for endocrine diseases